Tickling Tumor Cell Iron to Result in Surprising Pharmacology: Development of Innovative Anti-cancer Agents that Overcome P-Glycoprotein Resistance and Metastasis
Professor Richardson will discuss his translational studies developing the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein-mediated resistance and up-regulates the potent metastasis suppressor, NDRG1. These investigations constitute a major proportion of his research over his career. DpC underwent multi-centre Phase I clinical trials for the treatment of advanced and resistant cancer.